Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes

Drug Metabolism and Disposition

Volumn 40, Issue 2, 2012, Pages 389-396

  Mugundu, Ganesh M ^a   Sallans, Larry ^b   Guo, Yingying ^d   Shaughnessy, Elizabeth A ^c   Desai, Pankaj B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYTAMOXIFEN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; NORTAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL;

ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 CYP3A; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUBSTRATE SPECIFICITY; TAMOXIFEN;

EID: 84862930465     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039388     Document Type: Article

References (39)

1. Bao T, Prowell T, and Stearns V (2006) Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther 13:337-348. (Pubitemid 44492255)
2. Crewe HK, Ellis SW, Lennard MS, and Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178. (Pubitemid 27013472)
3. Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563. (Pubitemid 46628594)
4. Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, and Buckley AR (2002) Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 30:608-612. (Pubitemid 34456986)
5. Desta Z, Ward BA, Soukhova NV, and Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075. (Pubitemid 39108928)
6. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662. (Pubitemid 41672231)
7. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121. (Pubitemid 47555336)
8. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318.
9. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, and Desai PB (2004) Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273-1281. (Pubitemid 39391486)
10. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, and Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154. (Pubitemid 38373108)
11. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779. (Pubitemid 33151512)
13. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39.
14. Kim SY, Laxmi YR, Suzuki N, Ogura K, Watabe T, Duffel MW, and Shibutani S (2005) Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of α-hydroxytamoxifen in rat and human livers. Drug Metab Dispos 33:1673-1678. (Pubitemid 41539966)
15. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525. (Pubitemid 39100004)
16. Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, and Zembutsu H (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99:995-999. (Pubitemid 351997603)
17. Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, and Liu KH (2008) The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 36:986-990. (Pubitemid 351717478)
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. (Pubitemid 32268418)
19. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294. (Pubitemid 35284253)
20. Langenegger T, Wahl P, Schiesser D, and Thürlimann B (2006) Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. Breast Cancer Res Treat 100:177-181. (Pubitemid 44631919)
21. Ligibel JA and Winer EP (2005) Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res 7:255-257. (Pubitemid 41830163)
22. Lim YC, Li L, Desta Z, Zhao Q, Rae JM, Flockhart DA, and Skaar TC (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther 318:503-512. (Pubitemid 44061223)
23. Lønning PE, Lien EA, Lundgren S, and Kvinnsland S (1992) Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327-358.
24. Morello KC, Wurz GT, and DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361-372. (Pubitemid 36433876)
25. Nallani SC, Genter MB, and Desai PB (2001) Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 48:115-122. (Pubitemid 32710222)
26. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830. (Pubitemid 34603446)
27. Notley LM, Crewe KH, Taylor PJ, Lennard MS, and Gillam EM (2005) Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its α-hydroxy and α,4-dihydroxy derivatives. Chem Res Toxicol 18:1611-1618. (Pubitemid 41504482)
28. Ogura K, Ishikawa Y, Kaku T, Nishiyama T, Ohnuma T, Muro K, and Hiratsuka A (2006) Quaternary ammonium-linked glucuronidation of trans-4- hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 71:1358-1369.
29. Poon GK, Chui YC, McCague R, Lłnning PE, Feng R, Rowlands MG, and Jarman M (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119-1124. (Pubitemid 23348351)
30. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
31. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436.
32. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, and Duffel MW (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 58:647-653. (Pubitemid 28099473)
33. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, and Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764. (Pubitemid 38008898)
34. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Daly AK (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235. (Pubitemid 37339651)
35. Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, and Flaws JA (2005) Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 217:61-72.
36. Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, and Wingren S (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7.
37. White IN (1999) The tamoxifen dilemma. Carcinogenesis 20:1153-1160.
38. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891. (Pubitemid 34815417)
39. Xu Y, Sun Y, Yao L, Shi L, Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, et al. (2008) Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423-1429.